Sabril and Disease progression - a phase IV clinical study of FDA data

Summary:

Disease progression is reported as a side effect among people who take Sabril (vigabatrin), especially for people who are female, 2-9 old, have been taking the drug for < 1 month also take Onfi, and have Epilepsy.

The phase IV clinical study analyzes which people have Disease progression when taking Sabril. It is created by eHealthMe based on reports of 12,433 people who have side effects when taking Sabril from the FDA, and is updated regularly.

What is Sabril?

Sabril has active ingredients of vigabatrin. eHealthMe is studying from 12,445 Sabril users. Check the latest studies of Sabril.

What is Disease progression?

Disease progression is found to be associated with 1,802 drugs and 2,253 conditions by eHealthMe. Check the latest studies of Disease progression.

On Jul, 11, 2026

12,433 people reported to have side effects when taking Sabril.
Among them, 21 people (0.17%) have Disease progression.

Among these 21 people:

How long have people been on Sabril when they have Disease progression? *

What is the gender of people who have Disease progression when taking Sabril? *

female: 52.63 %
male: 47.37 %

What is the age of people who have Disease progression when taking Sabril? *

What are other drugs people take besides Sabril? *

What are other side effects people have besides Disease progression? *

Seizures (abnormal excessive or synchronous neuronal activity in the brain): 5 people, 23.81%
Respiratory Acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease): 3 people, 14.29%
Drowsiness: 3 people, 14.29%
Hypervolaemia (abnormally increased volume of blood): 2 people, 9.52%
Fatigue (feeling of tiredness): 2 people, 9.52%
Mitochondrial Encephalomyopathy (a condition that affects many of the body's systems, particularly the brain): 2 people, 9.52%
Metabolic Acidosis (body produces too much acid, or when the kidneys are not removing enough acid from the body): 2 people, 9.52%
Hyperkalemia (damage to or disease of the kidney): 2 people, 9.52%
Gastroenteritis (inflammation of stomach and intestine): 2 people, 9.52%
Focal Segmental Glomerulosclerosis (scar tissue that forms in parts of the kidney called glomeruli): 2 people, 9.52%

What are the existing conditions these people have? *

Infantile Spasms: 6 people, 28.57%
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 6 people, 28.57%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 5 people, 23.81%
Lennox-Gastaut Syndrome (epilepsy characterized by frequent seizures and different seizure types): 3 people, 14.29%
Chronic Renal Failure (kidney failure): 2 people, 9.52%
Tuberous Sclerosis (a rare genetic disease that causes benign tumours to grow in the brain and other organs): 1 person, 4.76%
Tonic Convulsion (the person will quickly lose consciousness and the skeletal muscles will suddenly tense, often causing the extremities to be pulled towards the body or rigidly pushed away from it): 1 person, 4.76%
Idiopathic Generalised Epilepsy (epileptic disorders that are believed to have a strong underlying genetic basis): 1 person, 4.76%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 4.76%
High Blood Pressure: 1 person, 4.76%

* Approximation only. Some reports may have incomplete information.

Do you take Sabril and have Disease progression?

- Check whether Disease progression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Sabril:

Sabril (12,445 reports)

Browse all side effects of Sabril:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Disease progression:

Disease progression (1,802 drugs)

Browse all the conditions that are associated with Disease progression:

Disease progression (2,253 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on vigabatrin (the active ingredients of Sabril) and Sabril (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.